enquiry@dsij.in |+91 9240904920
SENSEX-318.56
81,592.45-0.39%

Alkem Laboratories sees non-US growth while Daman issues delay earnings revival to FY28

Alkem Laboratories Ltd.

Broker Recommendation:

Neutral

Broker: Motilal Oswal

12 Nov 2026

Sector: Healthcare

Original PDF
Reco. Price

₹5,302

CMP

₹5,110

Target

₹5,890

Upside

11.09%

Investment View and Rating

In its November 12, 2026 results update, Motilal Oswal retained its Neutral rating on Alkem Laboratories. The broker expects FY27 to be a consolidation year, as new businesses face a gestation period, operating costs are front-loaded and revenues have yet to scale up. Regulatory issues at the Daman facility continue to weigh on financial performance and new ANDA approvals.

Motilal Oswal expects earnings growth to revive in FY28E as the biotech and med-tech businesses scale up and the India operations gain operating leverage.

2QFY27 Financial Performance

Alkem reported 2QFY27 revenue of Rs 4,552 crore, up 13.8 per cent YoY and broadly in line with expectations. Revenue and EBITDA were marginally ahead of Motilal Oswal's estimates by around 4 per cent and 3 per cent, respectively, supported by better international performance, principally outside the US.

Metric 2QFY27 YoY change
Revenue Rs 4,552 crore 13.8% increase
Gross margin 67.2% 220 bps expansion
EBITDA Rs 1,025 crore 11.3% increase
EBITDA margin 22.5% 50 bps decline
Adjusted PAT Rs 652 crore 14.8% decline

Higher employee costs and R&D expenditure offset the benefit from the improved mix, resulting in a 50-basis-point YoY decline in EBITDA margin to 22.5 per cent. Adjusted PAT fell 14.8 per cent YoY to Rs 652 crore, broadly in line with estimates, owing to higher depreciation and tax. The result included a Rs 35 crore exceptional recovery against an impaired investment.

In 1HFY27, revenue and EBITDA rose 12 per cent and 8 per cent YoY to Rs 8,290 crore and Rs 1,790 crore, respectively, while PAT declined 17 per cent YoY to Rs 1,170 crore.

Domestic and International Business Performance

Domestic formulations revenue grew 9.5 per cent YoY to Rs 3,028 crore, representing 67 per cent of sales. Alkem outperformed the industry in chronic therapies, although mid-single-digit trade-generics growth was constrained by intensifying competition and tighter credit policies.

International revenue rose 22.3 per cent YoY to Rs 1,451 crore. US generics sales increased 2.4 per cent YoY to Rs 783 crore despite robust volume growth, as stronger price erosion and the gradual scale-up of products including g-tolvaptan affected sales. Other international sales rose 58.2 per cent YoY to Rs 671 crore, driven by execution in Latin America and delivering Alkem's highest quarterly non-US sales.

Vriddhi_Growth.webp

Participating in Future Growth Themes

Structural changes and innovation can create long-term investment opportunities. DSIJ's Vriddhi Growth focuses on businesses positioned around emerging trends and scalable growth opportunities.

Management Outlook and Guidance

Management guided for around 11 per cent India-business growth in FY27, mid-single-digit US revenue growth in constant currency, and mid-to-high-teen non-US growth in FY27. Non-US growth is expected to sustain at mid-teens in FY28.

  • Around eight Daman-filed products are scheduled for launch within six to 12 months, although three key launches have been delayed while regulatory issues are addressed.
  • Trade-generics performance is expected to improve in 2HFY27.
  • The benefit of minimum import price measures on penicillin and amoxicillin is expected to be fully reflected from 2HFY27.
  • R&D spending guidance remains at 4 per cent to 4.5 per cent of revenue.

New Businesses and Investment Requirements

New businesses remain an important source of potential growth as well as near-term dilution. Core pharma EBITDA margin was about 26 per cent in 2QFY27, while Occlutech caused around 80 basis points of dilution.

Enzene

Management expects Enzene revenue to double over four years and reach EBITDA breakeven in two years. The business requires incremental capex of Rs 300 crore to Rs 350 crore over three to four years. Enzene has been affected by the denosumab BLA setback, a slower US CDMO ramp-up and higher B2B biosimilar price erosion.

Med-tech

Med-tech revenue is expected to grow three times over five to six years and reach EBITDA breakeven in one year. Incremental capex of Rs 400 crore is expected over three to four years.

Estimates and Valuation

Motilal Oswal largely maintained its FY27E and FY28E estimates.

Metric FY27E FY28E
Revenue Rs 16,560 crore Rs 18,290 crore
EBITDA Rs 3,430 crore Rs 4,060 crore
Adjusted PAT Rs 2,229 crore Rs 2,612 crore

The broker forecasts international-market sales CAGR of 11.8 per cent to Rs 5,850 crore over FY26 to FY28. It values Alkem at 27 times 12-month forward earnings to derive a target price of Rs 5,890.

Key Factors Affecting the Thesis

  • US price erosion.
  • Delayed Daman launches and the timing of regulatory resolution.
  • Competition in trade-generics.
  • The pace and profitability of biotech and med-tech scale-up.
Download Original Research Report

Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.